About Alkem Laboratories Limited

Alkem Laboratories Limited is an Indian pharmaceutical company established in 1973, with 50+ years of growth and a rank as the 5th largest pharma company in India by market share. The company focuses on branded and trade generics, biosimilars, and medical devices, and also offers Bio Contract Development and Manufacturing (BioCDMO) services through Enzene Biosciences. Its revenue mix is predominantly from India, contributing ~70% in recent years, alongside fast-growing international operations with 30%+ contribution. The company has a meaningful presence across 10+ countries and reports an international revenue contribution split of 22% from the US and ~10% from RoW markets.

Alkem operates 19 manufacturing facilities, including 5 that are USFDA-approved, and 4 R&D centres spanning sites such as Baddi, Sikkim, Daman, Taloja and Pune in India, plus facilities in California and an expected New Jersey site slated to be operational in late FY25. Its platforms cover tablets, injectables, APIs, biosimilars and more than 10 technology platforms.

Alkem Laboratories Limited Milestone

Key milestones include the first plant at Taloja, Mumbai (1978); first R&D facility at Taloja (2003); India’s first anti-infective drug to cross Rs 100 crore annual domestic sales (Taxim, 2006); first US ANDA filing (2007) and approval (2009); acquisitions in the US and Australia (2010–2012); IPO (2015); US annual sales crossing US$ 200 Million (2018); revenue crossing US$ 1 billion (2019); a new biologic/biosimilar facility in Pune (2020); Enzene’s first India launch (2021); and the launch of Eyecare (Ophthalmology) division and the 50-year milestone (2023).

Alkem Laboratories Limited’s Business Segments

• Domestic vs. International: ~70% of revenue from India; 30%+ from International, with 22% from the US and ~10% from RoW.
• Segment/vertical: Chronic therapies contributed 17% of revenue in FY24; Trade Generics (TGx) contributes 20%+ of India revenue.

Alkem Laboratories Limited Key Management

• Dr. Vikas Gupta – Chief Executive Officer
• Nitin Agarwal – Chief Financial Officer
• Amit Ghare – Head, International Business
• Sunil Pathak – Head, India Rx (Semi-Chronic)
• Mukesh Tiwari – Head, India Trade Gx
• Dr. Akhilesh Sharma – Chief Medical Officer
• Dr. Adil Billimoria – Chief Quality Officer
• Ashish Sehgal – Head, R&D and Regulatory Affairs
• Kaustav Banerjee – CEO, Alkem Medtech
• Dr. Himanshu Gadgil – CEO, Enzene
• Manish Narang – President – Legal, Company Secretary & Compliance Officer

Latest Updates on Alkem Laboratories Limited

• Q3 FY25 Performance: In Q3 FY25, Alkem received two USFDA approvals (including one tentative). Domestic sales formed 71.1% of total sales versus 68.6% a year ago; International sales recorded a YoY de-growth of 6.2%. EBITDA margin improved to 22.5% from 21.3%.
• 9M FY25 Highlights: For 9M FY25, domestic sales contributed 70.6% of total sales; the company’s EBITDA margin rose to 21.6%. As of December 31, 2024, Alkem had filed 179 ANDAs and 2 NDAs, and received 154 approvals (including 15 tentative) and 2 NDA approvals; net cash stood at Rs 4,700 crore.
• Enzene Business Update: Enzene’s differentiated continuous manufacturing technology underpins its BioCDMO business, which has delivered 40+ projects globally with 10+ in late-stage/commercialisation; its US facility is expected to go live in late FY25.